In the relentless human effort to tame a pandemic, not every promising path leads forward. Vir Biotechnology learned this on a Thursday morning in early March 2021, when an independent safety board recommended halting enrollment in a Phase 3 NIH trial of its monoclonal antibody VIR-7831, developed alongside GlaxoSmithKline, after the therapy failed to demonstrate meaningful benefit in hospitalized COVID-19 patients. The news sent Vir shares falling and served as a quiet reminder that in medicine, as in life, safety and efficacy are not the same promise — and that hope, however earnest, must ul
MarketWatch
· Mar 04, 2021
· health
· 1 min de leitura
High
Apuração: Verificado
NIH halts Vir COVID therapy trial after safety board finds no patient benefit
◉
Health & Medicine
8098 artigos relacionados
Moderna's personalized mRNA melanoma vaccine shows promise in preventi…
CBS News · 100% correspondência
Blood test could predict Covid-19 mortality risk, study finds
BreakingNews.ie · 99% correspondência
Hadassah performs world's first alpha radiation treatment for recurren…
jpost.com · 99% correspondência
Dr. Reddy's Wins Semaglutide Approval as Novo Nordisk Patent Challenge…
NDTV Profit · 99% correspondência
EU safety committee reviews reports of menstrual changes after mRNA CO…
CNBC · 99% correspondência
Cobertura Relacionada
The Guardian · Aug 20
Hundreds of thousands await GCSE results as gender gap narrows to 10-year low
Hundreds of thousands of UK students received GCSE results showing overall grade improvements in 2025, with the gender g…
The Straits Times · Aug 20 Ebola spreads beyond Congo epicentre, overwhelming treatment capacityEbola cases in DRC are accelerating outside the initial Ituri epicenter, with North Kivu and Haut-Uélé provinces experie…
Science Daily · Aug 20 1,000+ genetic switches explain why women face higher autoimmune disease riskResearchers identified over 1,000 genetic switches that function differently in male and female immune cells, explaining…
News-Medical · Aug 20 Brain's Local Wiring May Buffer Cognitive Decline in Older AdultsUSC researchers found that white matter integrity helps protect cognitive function in older adults by compensating for g…
Viés e Enquadramento
Não há dados de análise detalhada para esta lente. Tente executar as lentes novamente no painel de administração.
Impacto Geopolítico
🌎
NIH halts COVID-19 monoclonal antibody trial for lack of patient benefit, primarily a biotech/pharmaceutical development issue with minimal geopolitical significance.
Escalation Risk
low
Confidence
HIGH
No meaningful shifts in international power dynamics; this is a domestic U.S. clinical trial outcome affecting private biotech companies (Vir, GSK) and pharmaceutical markets.
Lente Econômica
📈
NIH halts Vir's COVID-19 monoclonal antibody trial after safety board finds no patient benefit, causing Vir shares to drop 27.64% and signaling setback for biotech pipeline.
Market Signal
bearish
Confidence
HIGH
Biotechnology/Pharmaceuticals
Healthcare
Medical Devices & Diagnostics
Consumers lose access to a potential treatment option for hospitalized COVID-19 patients; delays in alternative therapeutic options may prolong reliance on existing approved treatments like remdesivir.
Reinforces FDA/NIH rigorous clinical trial standards; may accelerate regulatory focus on monoclonal antibody efficacy requirements; could influence future biotech R&D investment priorities toward more proven therapeutic approaches.